Form 4: Virios Therapeutics' Chief Medical Officer Granted Stock Options

Roger Michael Gendreau, Chief Medical Officer of Virios Therapeutics, Inc., was granted stock options to purchase 88,085 shares of common stock on February 26, 2024.

Summary

• On February 26, 2024, Roger Michael Gendreau, the Chief Medical Officer of Virios Therapeutics, Inc., was granted stock options.
• These options allow him to purchase 88,085 shares of the company's common stock at an exercise price of $0.357 per share.
• The stock options will vest 100% on February 26, 2025, one year after the grant date.
• The options expire on February 26, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to align executive incentives with shareholder value creation.
• The vesting schedule of one year is relatively standard, as it encourages executives to remain with the company for at least that period.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance drives the company's success.
• The grant incentivizes the Chief Medical Officer to contribute to the company's long-term growth.

Key Dates

Keywords

stock options, Virios Therapeutics, VIRI, Chief Medical Officer, Roger Michael Gendreau, executive compensation, Form 4, insider trading